PluroGen Therapeutics, Inc.
2495 General Armistead Avenue
Norristwon, Pennsylvania  19403
Tel:  +1 (434) 563-4321
Fax:  +1 (434) 563-4322
N e w s  R e l e a s e
February 18, 2011
Contact: Neal G. Koller    
President & CEO             
Board of Directors   
+1 (434) 563-4321
PluroGen Receives & Ships 1st Austrian Order for PluroGel® with Silver Sulphadiazine
Charlottesville, VA, 18 February 2011) – PluroGen Therapeutics, Inc. today announced that it has received
and shipped its first order to its Austrian distribution partner for PluroGel® with Silver Sulphadiazine.

Commenting on the first Austrian order, Neal G. Koller, President & CEO of PluroGen, said “Our new Austrian
distribution partner will provide a solid sales, marketing and distribution base for PluroGel® with Silver
Sulphadiazine.  They are an established company with long-term and excellent relationships in the Austrian
physician, hospital, nursing home and pharmacy markets.  We look forward to great success in Austria.”

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology
platforms.  The Company’s primary platform is its core PluroGel® technology which provides paradigm-
shifting, superior and differentiated physical, bio-impact, and multi-function products.  PluroGel® is University
developed and is in routine use at the University, having shown superior results on more than 10,000 patients
in two different patient populations - severe burns and wounds.  PluroGen’s three technology platforms are
configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment
in tissue management and healing:  1. Cleansing;  2. Anti-Infection;  3. Reduced Pain;  4. Anti-Inflammation;  5.
Tissue salvage;  6. Tissue regeneration.

PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel®
branded topical antimicrobial prescription products and PluroGel® co-branded products with select
commercial partners.

PluroGen’s senior management, operations team, boards and principal investigators are all recognized global
commercial and clinical leaders in PluroGen’s target markets of burn and wound care.

For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995.  PluroGen cautions readers that forward-looking statements are subject to
certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in
the Company’s reports filed with the U.S. Securities and Exchange Commission.  PluroGen Therapeutics, Inc. claims the
protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.